title: Interferon-gamma therapy for infection control in chronic granulomatous disease.
abstract: Interferon (IFN)-gamma was subcutaneously administered to four patients with chronic granulomatous disease (CGD) in order to evaluate its effects in controlling infection. Patients 1 to 3 were all males, while patient 4 was female. In patients 2 and 4, the length of infection-associated hospitalization during the year of IFN therapy was significantly shorter than that during the whole observed period prior to IFN therapy. In patients 1 and 2, the length of hospitalization during a year of IFN therapy was shorter than that during 1 year prior to the therapy. Patient 3 exhibited no reduction in terms of the length of infectious disease during IFN therapy, because he suffered from a liver abscess before and during the therapy. As soon as the IFN therapy was stopped, patient 2 developed pneumonia and lymphadenitis, which were promptly relieved by readministering the agent. During 1 year of IFN therapy, patients 1, 2 and 4 showed no significant changes in either the nitroblue tetrazolium test, O2- production or the expression of NADPH oxidase components in neutrophils. On the other hand, the O2- generating ability of neutrophils from patient 3 slightly increased. Our limited observations suggest that IFN-gamma may be variably beneficial for infection control in CGD-patients, irrespective of the in vitro phagocyte functions. A longer follow-up time is needed to confirm the IFN response in CGD-patients.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ohga
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: H
authors.initials: H
authors.lastname: Nakayama
authors.forename: Y
authors.initials: Y
authors.lastname: Nagatoshi
authors.forename: K
authors.initials: K
authors.lastname: Ueda
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000097:blood / Q000150:complications*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D015166:Monitoring, Immunologic; D009894:Opportunistic Infections / Q000517:prevention & control*; D012008:Recurrence; D013481:Superoxides / Q000378:metabolism
chemical_list: D013481:Superoxides; D007371:Interferon-gamma